Patients scheduled for TAVI tend to form abnormal fibrin clots more resistant to lysis: the impact of age

Jaworska-Wilczyńska, Maria; Natorska, Joanna; Siudut, Jakub; Marzec, Karolina; Kowalik, Ilona; Hryniewiecki, Tomasz

doi:10.33963/kp.a2021.0005

Cited by 10 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 30 Our research demonstrated that patients with stages 3-4 CKD, compared to patients with eGFR ≥ 60 mL/min/1.73 m 2 are characterized by higher fibrinogen levels, higher endogenous thrombin potential as a measure of thrombin formation, lower fibrin clot permeability as a measure of fibrin network density, and longer clot lysis time. 15 The prothrombotic fibrin clot phenotype reported in patients with several diseases associated with prothrombotic tendency 31 - 33 has also been observed in those with AF and CKD in relation to elevated NT-proBNP. 34 …”

Section: Prediction Of Major Adverse Events In Chronic Kidney Diseasementioning

confidence: 91%

Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues

Matusi¹,

Heleniak²,

Undas³

2022

The Anatolian Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Up to 20% of patients with chronic kidney disease have atrial fibrillation, and 40%-50% of atrial fibrillation patients suffer from chronic kidney disease. The 2 diseases share several risk factors and frequently coincide with each other. Both entities are associated with a prothrombotic state, which contributes to increased thromboembolic risk. Atrial fibrillation patients with chronic kidney disease have elevated risk of stroke, major bleeding, and mortality. Clinical risk scores, including CHA 2 DS 2 -VASc score, HAS-BLED score, or ORBIT score have a limited value in adverse clinical outcome risk stratification in patients with severe chronic kidney disease. However, the inclusion of renal function in the R (2) -CHA 2 DS 2 -VASc score does not improve significantly thromboembolic risk prediction in atrial fibrillation. There is growing evidence suggesting that biomarkers, including N-terminal pro-B-type natriuretic peptide, high-sensitivity cardiac troponin, cystatin C, or growth differentiation factor-15, might be helpful in the assessment of thromboembolic, bleeding, and/or mortality risk in atrial fibrillation patients with chronic kidney disease. The first-choice anticoagulant therapy is based on direct oral anticoagulants in this subgroup. The highest risk of adverse events is observed in end-stage renal disease, and in Europe, in contrast to the USA, solely warfarin is recommended in such atrial fibrillation patients. Treatment of atrial fibrillation patients with chronic kidney disease should be closely monitored with the selection of right anticoagulant agents at the appropriate dose. The current review paper summarizes available evidence and the challenges of the management of atrial fibrillation patients with chronic kidney disease with practical implications.

show abstract

Section: Prediction Of Major Adverse Events In Chronic Kidney Diseasementioning

confidence: 91%

Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues

Matusi¹,

Heleniak²,

Undas³

2022

The Anatolian Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In cancer patients, common comorbidities which typically affect older subjects prone to malignant diseases may have some impact on fibrin clot properties. There is strong evidence regarding prothrombotic fibrin clot properties in patients with cardiovascular disease 65 66 or prior VTE 67 as well as those with type 2 diabetes 68 or advanced kidney disease. 69 Taken together, comorbidities associated with prothrombotic fibrin clot phenotype 66 may heighten the risk of CAT, though available data supporting this concept are scarce.…”

Section: Fibrin Clot Properties In Specific Diseasesmentioning

confidence: 99%

Fibrin Clot Properties in Cancer: Impact on Cancer-Associated Thrombosis

Ząbczyk

Undas

2023

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

Cancer is associated with a high risk of venous thromboembolism (VTE) and its recurrence. There is evidence that the prothrombotic fibrin clot phenotype, involving the formation of denser and stiffer clots relatively resistant to lysis, occurs in cancer patients, which is in part related to enhanced inflammation, oxidative stress, and coagulation activation, along with the release of neutrophil extracellular traps, indicating that fibrin-related mechanisms might contribute to cancer-associated thrombosis (CAT). Multiple myeloma and its therapy have been most widely explored in terms of altered fibrin characteristics, but prothrombotic fibrin clot features have also been reported in patients with active solid cancer, including lung cancer and gastrointestinal cancer. Patient-related factors such as advanced age, smoking, and comorbidities might also affect fibrin clot characteristics and the risk of CAT. Prothrombotic fibrin clot features have been shown to predict the detection of cancer in patients following VTE during follow-up. Cancer-specific therapies and anticoagulation can favorably modify the phenotype of a fibrin clot, which may alter the course of CAT. It is unclear whether the fibrin clot phenotype might help identify patients with CAT who are more likely to experience recurrent events. This narrative review summarizes the current knowledge on the role of fibrin clot structure and function in cancer patients in the context of CAT.

show abstract

“…Calibrated Automated Thrombography (CAT; Thrombinoscope BV, Maastricht, the Netherlands), was used to measure endogenous thrombin potential (ETP). 22 The fluorometer (Ascent Reader, Thermolabsystems OY, Helsinki, Finland) was used to generate the area under the curve at 37°C. 20 µL of tissue factor (TF)-based activator (PPP Reagent containing 5 µmol/L recombinant TF and 4 µmol/L phospholipid vesicles; Diagnostica Stago) and FluCa solution (Diagnostica Stago) was added to 80 µL platelet-poor plasma.…”

Section: Endogenous Thrombin Potential (Etp)mentioning

confidence: 99%

Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation

Mołek

Chmiel

Ząbczyk

et al. 2022

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Patients scheduled for TAVI tend to form abnormal fibrin clots more resistant to lysis: the impact of age

Cited by 10 publications

References 32 publications

Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues

Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues

Fibrin Clot Properties in Cancer: Impact on Cancer-Associated Thrombosis

Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation

Contact Info

Product

Resources

About